TsCell Biotech

TsCell is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to the development of next-generation T-cell therapies. The company utilizes proprietary platforms to engineer γδ T cells and regulatory T cells (Tregs) for the treatment of solid tumors and autoimmune diseases. By focusing on these specific T-cell subsets, TsCell aims to provide off-the-shelf allogeneic solutions that offer improved safety profiles and broader therapeutic windows compared to conventional CAR-T therapies. The company's lead programs are currently advancing through early-stage clinical trials, supported by a strong network of venture capital investors. TsCell's approach leverages the unique biology of γδ T cells to achieve MHC-independent tumor recognition and the suppressive capabilities of Tregs to restore immune balance.